AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00233610
- Locations
- 🇮🇹
Research Site, Roma, Italy
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
Completed
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT00233649
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
Pulmicort Asthma Prevention (Post-PAC)
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00233584
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00232648
Efficacy Study of the Effect of Budesonide on Emphysema
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00232674
- Locations
- 🇩🇰
Research Site, Gentofte, Denmark
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 452
- Registration Number
- NCT00232661
- Locations
- 🇳🇱
Research Site, Sittard, Netherlands
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00230516
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2009-08-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 224
- Registration Number
- NCT00229723
- Locations
- 🇨🇳
Research Site, Taoynan, Taiwan
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00229684
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 317
- Registration Number
- NCT00229697
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath